Class / Patent application number | Description | Number of patent applications / Date published |
424249100 | Neisseria (e.g., Neisseria gonorrhoeae, etc.) | 32 |
20100047287 | OUTER MEMBRANE VESICLES AND USES THEREOF - The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally down-regulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection. | 02-25-2010 |
20100272758 | Viable non-toxic gram-negative bacteria - The present invention provides non-toxic Gram-negative bacteria. In particular, the present invention provides viable Gram-negative bacteria (e.g., | 10-28-2010 |
20100316675 | GLYCOSYLTRANSFERASES FOR BIOSYNTHESIS OF OLIGOSACCHARIDES, AND GENES ENCODING THEM - The present invention is directed to nucleic acids encoding glycosyltransferases, the proteins encoded thereby, and to methods for synthesizing oligosaccharides using the glycosyltransferases of the invention. In particular, the present application is directed to identification a glycosyltransferase locus of | 12-16-2010 |
20120027800 | NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS - The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response. | 02-02-2012 |
20120039942 | OUTER MEMBRANE VESICLES AND USES THEREOF - The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally down-regulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection. | 02-16-2012 |
20120093867 | GNA1870-Based Vesicle Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis - The present invention generally provides methods and compositions for eliciting an immune response against | 04-19-2012 |
20140234374 | COMPOSITIONS AND METHODS FOR ACTIVATING INNATE AND ALLERGIC IMMUNITY - Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma). | 08-21-2014 |
424250100 | Neisseria meningitidis | 25 |
20080233154 | Vaccine Composition - The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are | 09-25-2008 |
20090017073 | Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof - A method for modulating Nod1 activity wherein said method comprises the steps of providing cells expressing a functional Nod1: and bringing said cells into contact with a molecule related to compositions comprising a molecule related to MTP and use of a molecule related to MTP for modulating inflammation and/or apoptosis. | 01-15-2009 |
20090041807 | Stable Compositions Containing Omvs - An OMV preparation comprises OMVs having a sufficiently positive or negative surface charge to substantially prevent aggregation. | 02-12-2009 |
20090068229 | MODIFIED SURFACE ANTIGEN - Novel proteins that constitute modified forms of a | 03-12-2009 |
20090123499 | VACCINE - The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and more effective for use in human subjects. | 05-14-2009 |
20090208533 | NEISSERIA MENINGITIDIS SEROGROUP A CAPSULAR POLYSACCHARIDE ACETYLTRANSFERASE, METHODS AND COMPOSITIONS - Provided are methods for recombinant production of an O-acetyltransferase and methods for acetylating capsular polysaccharides, especially those of a Serogroup A | 08-20-2009 |
20100003283 | LIPID A DEFICIENT MUTANTS OF NEISSERIA MENINGITIDIS - The invention provides lipid A deficient mutant | 01-07-2010 |
20100092519 | COMPOSITIONS COMPRISING POLYSACCHARIDE CONJUGATES AND THEIR USE AS VACCINES - The present invention is in the field of combination therapies, including vaccine compositions, which comprise polysaccharide-protein conjugates and outer membrane vesicles (OMVs) from commensal bacteria, particularly commensal | 04-15-2010 |
20100143418 | Immunising Against Meningococcal Serogroup Y Using Proteins - The invention uses polypeptide antigens and/or OMVs to immunize against serogroups A, C, W | 06-10-2010 |
20100285069 | MENINGOCOCCAL VACCINE FORMULATIONS - A dual formulation for vaccines against | 11-11-2010 |
20110033500 | VACCINE COMPOSITIONS COMPRISING L2 AND/OR L3 IMMUNOTYPE LIPOOLIGOSACCHARIDES FROM LGTB-NEISSERIA MENINGITIDIS - The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtB | 02-10-2011 |
20110229522 | METHODS, COMPOSITIONS AND VACCINES RELATING TO NEISSERIA MENINGITIDIS ANTIBODIES - The invention provides compositions and methods for screening subjects at risk for contracting meningococcal disease and/or at risk for failing to elicit an immunogenic response to a vaccine against | 09-22-2011 |
20110256180 | Factor H Binding Proteins (FHBP) with Altered Properties and Methods of Use Thereof - Factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of | 10-20-2011 |
20110262484 | OUTER MEMBRANE VESICLE PRIME-PROTEIN BOOST VACCINE - The present invention provides a method of immunizing a subject against a disease caused by | 10-27-2011 |
20120027801 | POLYPEPTIDES FROM NEISSERIA MENINGITIDIS - Various specific meningococcal proteins are disclosed. The invention provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by meningococcus, such as bacterial meningitis. | 02-02-2012 |
20120064119 | NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS - The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response. | 03-15-2012 |
20120064120 | NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS - The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response. | 03-15-2012 |
20120121646 | Vaccine - The invention relates to a vaccine for the treatment of disease caused by | 05-17-2012 |
20130022639 | EXPRESSION OF MENINGOCOCCAL FHBP POLYPEPTIDES - The meningococcal fhbp gene (encoding factor H binding protein) is naturally expressed from two independent transcripts by two differentially regulated promoters. In one transcript it is co-expressed with the neighbouring upstream gene from the P | 01-24-2013 |
20130045231 | IMMUNOGENIC COMPOSITION - Compositions for the treatment or prevention of Neisserial infection and methods for their use and manufacture are provided herein. | 02-21-2013 |
20130089571 | Vaccine - The present invention relates to compositions comprising at least one purified PorA protein antigen and at least one purified FetA protein antigen. In particular, said PorA/FetA antigens are antigenically variable antigens comprising the variable regions of PorA/FetA. Specific combinations of PorA/FetA epitopes are presented for example in Table 3. The invention also relates to methods of immunisation comprising administering said compositions, and to methods for producing compositions. Preferably the compositions are purified protein compositions. Preferably the compositions are vaccine compositions. | 04-11-2013 |
20130171194 | STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS - The present invention relates to stable formulations of | 07-04-2013 |
20140147469 | PROCESS FOR DETERGENT-FREE PRODUCTION OF OUTER MEMBRANE VESICLES OF A GRAM-NEGATIVE BACTERIUM - The present invention relates to the fields of medical microbiology and vaccines. In particular the invention relates to a process for detergent-free preparation of outer membrane vesicles (OMV) of Gram negative bacteria for use in vaccines, to OMV obtainable by said process, and to a pharmaceutical composition comprising such OMV. The present invention further relates to the use of OMV of the present invention as a medicament in particular for use in a method for eliciting an immune response. | 05-29-2014 |
20150147356 | ANTIPYRETICS TO ENHANCE TOLERABILITY OF VESICLE-BASED VACCINES - A method for immunising a human subject, wherein the subject receives (i) an immunogenic composition comprising bacterial vesicles and (ii) an antipyretic, and wherein the immunogenic composition and the antipyretic are administered to the subject within 24 hours of each other. Paracetamol significantly reduces fever rates without negatively affecting the immunogenicity either of a meningococcal vesicle vaccine or of concomitantly-administered antigens. | 05-28-2015 |
20160175423 | VACCINE COMPOSITION | 06-23-2016 |